



# Document details

📄 Export 📄 Download 🖨️ Print ✉️ E-mail 📄 Save to PDF ☆ Add to List More... >

[View at Publisher](#)

Lung Cancer  
Volume 136, October 2019, Pages 65-73

## Molecular testing for advanced non-small cell lung cancer in Malaysia : Consensus statement from the College of Pathologists, Academy of Medicine Malaysia , the Malaysian Thoracic Society, and the Malaysian Oncological Society (Review) (Open Access)

Rajadurai, P.<sup>a,b</sup> ✉️, Cheah, P.L.<sup>c</sup> ✉️, How, S.H.<sup>d</sup> ✉️, Liam, C.K.<sup>e</sup> ✉️, Annuar, M.A.A.<sup>f</sup> ✉️, Omar, N.<sup>g</sup> ✉️, Othman, N.<sup>g</sup> ✉️, Marzuki, N.M.<sup>h</sup> ✉️, Pang, Y.K.<sup>c</sup> ✉️, Bustamam, R.S.A.<sup>g</sup> ✉️, Tho, L.M.<sup>i</sup> ✉️ 👤

<sup>a</sup>Subang Jaya Medical Centre, 47500 Subang Jaya, Selangor, Malaysia  
<sup>b</sup>Monash University Malaysia, 47500 Subang Jaya, Selangor, Malaysia  
<sup>c</sup>University Malaya Medical Centre, Kuala Lumpur, 50603, Malaysia

[View additional affiliations](#) ▾

### Abstract

In the recent years, increased understanding of the molecular profiles of non-small cell lung cancer (NSCLC) has allowed for targeted treatment of actionable genetic mutations. The management of NSCLC now requires multiple molecular tests to guide the treatment strategy. In the light of this, there is a need to establish a molecular testing consensus statement for advanced NSCLC patients in Malaysia. This Malaysian consensus statement was developed by a panel of experts, chaired by a pathologist and composed of three other pathologists, four respiratory physicians and three oncologists. It reflects currently available scientific data and adaptations of recommendations from international guidelines to the local landscape. Expert recommendations on different aspects of molecular testing agreed upon by the panel are provided as structured discussions. These recommendations address the appropriate patients and samples to be tested, as well as when and how these tests should be performed. The algorithms for molecular testing in metastatic NSCLC, in the first line setting and upon disease progression beyond first line therapy, were developed. © 2019 The Authors

### SciVal Topic Prominence ⓘ

Topic: Immunotherapy | Neoplasms | Checkpoint inhibitor

Prominence percentile: 99.995 ⓘ

### Author keywords

Guidelines Molecular testing Non-small cell lung cancer Targeted therapy Tissue biopsy

### Indexed keywords

EMTREE drug terms: atezolizumab avelumab B Raf kinase durvalumab epidermal growth factor receptor epidermal growth factor receptor 2 nivolumab pembrolizumab programmed death 1 ligand 1 protein Ret

Metrics ⓘ [View all metrics](#) >

1 Citation in Scopus  
Field-Weighted  
Citation Impact



PlumX Metrics ▾  
Usage, Captures, Mentions,  
Social Media and Citations  
beyond Scopus.

### Cited by 1 document

Lung Cancer in Malaysia  
Rajadurai, P. , How, S.H. , Liam, C.K.  
(2020) *Journal of Thoracic Oncology*

[View details of this citation](#)

Inform me when this document is cited in Scopus:

[Set citation alert >](#)

[Set citation feed >](#)

### Related documents

Find more related documents in Scopus based on:

[Authors](#) > [Keywords](#) >

EMTREE medical terms:

ALK gene BRAF gene cancer growth cancer immunotherapy cancer tissue  
carcinogenesis consensus diagnostic accuracy EGFR gene genetic screening  
HER2 gene human liquid biopsy lung metastasis Malaysia medical school  
medical society MET gene molecular diagnosis molecular genetics  
next generation sequencing non small cell lung cancer nonhuman NTRK1 gene  
oncogene oncogene K ras oncologist oncology pathologist practice guideline  
primary health care priority journal pulmonologist RET gene Review ROS1 gene  
treatment outcome

---

## Chemicals and CAS Registry Numbers:

atezolizumab, 1380723-44-3; avelumab, 1537032-82-8; durvalumab, 1428935-60-7; epidermal growth factor receptor, 79079-06-4; epidermal growth factor receptor 2, 137632-09-8; nivolumab, 946414-94-4; pembrolizumab, 1374853-91-4; protein Ret, 154251-46-4, 158709-11-6

---

## Manufacturers:

Drug manufacturer:

Hoffmann La Roche, Switzerland;

Merck Serono, Germany;

Astra Zeneca, United Kingdom;

Bristol Myers Squibb, United States;

Genentech, United States;

Medimmune, United States;

Merck, United States;

Pfizer, United States

---

## Funding details

Funding text #1

Disclosure of interests and activities by members of the expert panel are listed in the Appendix. This consensus statement was funded by the College of Pathologists, Academy of Medicine Malaysia.

Funding text #2

This consensus statement was funded by the College of Pathologists, Academy of Medicine Malaysia . The College of Pathologists, Academy of Medicine Malaysia plays no role in the manuscript preparation. We would also like to acknowledge MediConnexions Consulting Pte Ltd for their editing assistance.

---

ISSN: 01695002

CODEN: LUCAE

Source Type: Journal

Original language: English


DOI: 10.1016/j.lungcan.2019.08.005

PubMed ID: 31446227

Document Type: Review

Publisher: Elsevier Ireland Ltd

---

 Rajadurai, P.; Subang Jaya Medical Centre, 1, Jalan SS 12/1A, Subang Jaya, Selangor, Malaysia;  
email:drpathma@gmail.com

© Copyright 2019 Elsevier B.V., All rights reserved.